Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations


  • The opinions expressed in this article are those of the authors and do not necessarily reflect those of the US Food and Drug Administration. As such, no official support for or endorsement of this article by the US FDA is intended or should be inferred.

  • Potential conflict of interest: The FDA Ethics Committee screened all participants with potential conflicts of interest and granted waivers for participants selected to participate in the Advisory Meeting process.